AltrixBio is a pharmaceutical company focused on oral drug that replicates the metabolic success of bariatric surgery.
AltrixBio has raised $1.2M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2025.
AltrixBio's investors include Flybridge, Taihill Venture, XFactor Ventures, Walnut Venture Associates, Arizona Tech Investors.
AltrixBio is headquartered in Cambridge, United States.
AltrixBio is a pharmaceutical company focused on oral drug that replicates the metabolic success of bariatric surgery.
AltrixBio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AltrixBio — Funding & Investors." VCBacked, May 5, 2025, https://www.vcbacked.co/company/altrixbio. Accessed July 19, 2026.
VCBacked. (2025). AltrixBio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/altrixbio
{{cite web |title=AltrixBio — Funding & Investors |url=https://www.vcbacked.co/company/altrixbio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated